^
Association details:
| Biomarker: | BRAF V600K |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) + lacnotuzumab (MCS110) (CSF-1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
Published date:
04/25/2023
Excerpt:
We performed a phase I/II study to determine the safety and efficacy of CSF1 inhibition with MCS110 in combination with BRAF/MEK inhibition with dabrafenib/trametinib in patients with BRAF V600E/K mutant metastatic melanoma….One patient had a partial response (PR) by RECIST 1.1, one patient had stable disease (SD), 3 patients had disease progression (PD)....One response was observed in this small sample of patients suggesting this combination might be worthy of further exploration.
DOI:
10.1007/s10637-023-01364-5
